Active Filter(s):
Details:
Under the terms of the agreement, Kamada Inc., will be responsible for the commercialization of the CYTOGAM®, WINRHO®, HEPAGAM B®, and VARIZIG® in the U.S., including direct sales to wholesalers and local distributers.
Lead Product(s): Cytomegalovirus Immune Globulin [Human],Ganciclovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Cytogam
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Kamada
Deal Size: $145.0 million Upfront Cash: $95.0 million
Deal Type: Acquisition November 22, 2021